<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833131</url>
  </required_header>
  <id_info>
    <org_study_id>PGBRJG0109</org_study_id>
    <nct_id>NCT00833131</nct_id>
  </id_info>
  <brief_title>The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer</brief_title>
  <official_title>Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Colorectal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of Oxaliplatin to conventionally fractionated chemoradiation (FULV or
      capecitabine) is considered as standard in unresectable rectal cancer by the panel of
      experts. The Investigators addressed the question whether short-course preoperative
      radiotherapy with consolidating chemotherapy of FOLFOX4 may increase the rate of R0 resection
      in patients with unresectable rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with unresectable primary rectal cancer or with unresectable local recurrence
      without distant metastases are randomly allocated to control or experimental arm. The
      preoperative treatment in the control arm is conventionally fractionated chemoradiation with
      50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks simultaneously with 5-Fu,
      leucovorin and oxaliplatin. Experimental group receive 25 Gy in 5 fractions of 5 Gy over 5
      days and after one week interval - consolidating chemotherapy of 3 courses of FOLFOX4.
      Surgery should be curried out 10-11 weeks from beginning of radiation and at least 4 weeks
      from the last dose of fluorouracil or radiation. The study hypothesis is that the
      short-course preoperative radiotherapy with consolidating chemotherapy produce at least 10%
      increase of the rate of R0 resection compared to preoperative chemoradiation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients with R0 resection</measure>
    <time_frame>Surrogate endpoint available immediatly after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall long-term survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free long-term survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of local failures</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of distant metastases</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 3.0)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of postoperative complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of late toxicity according to the RTOG/EORTC scale</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of complete pathological response</measure>
    <time_frame>Surrogate endpoint available immediatly after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 Gy in 5 fractions of 5 Gy over 5 days. One week interval. Consolidating chemotherapy of 3 courses of FOLFOX4. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of fluorouracil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventionally fractionated chemoradiation with 50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short course of radiotherapy</intervention_name>
    <description>5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4</description>
    <arm_group_label>1</arm_group_label>
    <other_name>short radiation</other_name>
    <other_name>consolidating chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiochemotherapy</intervention_name>
    <description>28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>chemoradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unresectable primary rectal cancer or with unresectable local recurrence
             without distant metastases.

          -  WHO performance status ≤ 2.

          -  Lower border of tumour ≤ 15 cm from anal verge.

        Exclusion Criteria:

          -  cardiac coronary arterial disease,

          -  arrhythmias,

          -  stroke even if they have occurred in the past and are controlled with medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krzysztof Bujko, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roentgena 5, 02-781 Warsaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Michalski, M. S.</last_name>
    <phone>+48226433909</phone>
    <email>W.Michalski@coi.waw.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>M. Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Bujko, Prof.</last_name>
      <phone>+48226439287</phone>
      <email>bujko@coi.waw.pl</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Bujko, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Bujko K, Kolodziejczyk M. The 5 x 5 Gy with delayed surgery in non-resectable rectal cancer: a new treatment option. Radiother Oncol. 2008 Jun;87(3):311-3. doi: 10.1016/j.radonc.2007.12.020. Epub 2008 Jan 18.</citation>
    <PMID>18207596</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <last_update_submitted>April 14, 2010</last_update_submitted>
  <last_update_submitted_qc>April 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Marek P. Nowacki</name_title>
    <organization>Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology in Warsaw</organization>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>Preoperative radiotherapy and consolidating chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

